Facebook
X
LinkedIn
Forward
Rheumatology Association of Iowa Annual Meeting
| Registration |
|---|
Target Audience
Healthcare professionals who care for patients with rheumatic diseases, including rheumatologists and other clinicians and healthcare professionals working in rheumatology settings.
Educational Need
Rheumatology professionals must remain current on both the clinical management of complex rheumatic diseases and changes in the healthcare environment that affect patient care. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) can result in significant morbidity and mortality, making early recognition, appropriate screening, and timely treatment essential. At the same time, evolving federal and state policies, legislation, reimbursement models, and advocacy priorities can affect clinical practice and patients’ access to care. Education is needed to strengthen clinicians’ ability to identify and manage SSc-ILD while understanding policy developments that may influence rheumatology practice and patient care.
Description
This educational activity addresses current clinical and policy issues relevant to rheumatology practice. Participants will review approaches to screening for and diagnosing early interstitial lung disease in patients with systemic sclerosis and examine FDA-approved treatment options for SSc-ILD. The activity will also explore federal and state policy developments affecting rheumatology, including potential implications for clinical practice, reimbursement, and healthcare delivery. Participants will consider opportunities for professional advocacy and engagement at the state and national levels.
Objectives
- Apply appropriate screening and diagnostic approaches to identify interstitial lung disease early in patients with systemic sclerosis.
- Discuss FDA-approved therapies for systemic sclerosis-associated interstitial lung disease, including their appropriate use in clinical practice.
- Identify changes in federal and state policies that may affect rheumatology practice and patient care.
- Evaluate the potential implications of emerging legislation for clinical practice, reimbursement, and healthcare delivery.
- Identify opportunities for professional advocacy and legislative engagement at the state and national levels.
Agenda
| Friday, February 25, 2022 | ||
|---|---|---|
| 5:00 pm | Welcome | |
| 5:10 pm | Advocacy Update Michael S. Brooks, MD, FACP, FACR | |
| 6:10 pm | Adjourn | |
| Saturday, February 26, 2022 | ||
|---|---|---|
| 9:00 am | Welcome | |
| 9:15 am | Scleroderma Dinesh Khanna, MBBS, MSc This session will examine the recognition, screening, diagnosis, and management of systemic sclerosis, with particular emphasis on systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants will review strategies for identifying early pulmonary involvement, appropriate diagnostic evaluation and monitoring, and current FDA-approved treatment options. The session will emphasize timely recognition and management of internal organ complications to support informed clinical decision-making and improve outcomes for patients with scleroderma. | |
| 10:15 am | Break | |
| 10:45 am | Lung Disease and Scleroderma Dinesh Khanna, MBBS, MSc Systemic sclerosis (SSc), or scleroderma, is a complex rheumatic disease characterized by autoimmunity, vasculopathy, and progressive fibrosis of the skin and internal organs. Internal organ involvement contributes substantially to morbidity and mortality, with interstitial lung disease representing a significant complication of SSc. Rheumatologists and other clinicians caring for patients with SSc need the knowledge and skills to recognize risk factors and early manifestations of organ involvement, implement appropriate screening and diagnostic strategies, and initiate or coordinate timely treatment. Education is needed to support earlier identification and evidence-based management of SSc-associated interstitial lung disease and other complications to improve patient outcomes. | |
| 11:45 am | RAI Annual Business Meeting | |
| 12:30 pm | Lunch | |
| 1:30 pm | Dessert | |
| 2:00 pm | Local and Federal Advocacy Panel Brian Henderson Dennis Tibben, MPA For physicians focused on delivering care, it is hard to keep track of legislative and regulatory developments that will ultimately affect how they provide that care. As rheumatologists, it's important to stay informed about socioeconomic activity in Washington and at the local level, especially how new initiatives will affect our patients and practice. Rheumatologists need to understand federal, Iowa state, and local legislation and regulations related to medication access, practice management, private payer reform, and administrative simplification, and how they affect practice success and the quality of patient care. | |
| 3:30 pm | Adjourn | |
Questions
RAI Executive Office
847-517-7225
[email protected]
Course summary
- 4.50 AMA PRA Category 1 Credits™
- 4.50 AOA 2-A
- 4.50 CE Contact Hour(s)
Accreditation Statements
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 4.50 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Des Moines University (DMU) and the Rheumatology Association of Iowa. DMU is accredited by IMS to provide continuing medical education for physicians. DMU designates this live activity for a maximum of 4.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 4.50 continuing education contact hour(s). Nurses must attend the entire session to receive credit. Partial session credit is prohibited and will be forfeited.
- Other: This live activity is designated for 4.50 AMA PRA Category 1 Credit(s)TM.
Educational Grants
No ineligible company provided financial support for this continuing education activity.
Disclosure
The speaker(s) will disclose if any pharmaceuticals, medical procedures, or devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). The activity directors are responsible for determining educational content and selecting speakers.
Relevant to the content of this educational activity, the following individual(s) have no conflict(s) with ineligible companies to disclose.
- Michael S. Brooks, MD, FACP, FACR - Speaker
- Bogdan Cherascu, MD, MS - Activity Director, Planning Committee Member, and Moderator
- Lorene Harder - Activity Coordinator and Planning Committee Member
- Brian Henderson - Speaker
- Dennis Tibben, MPA - Speaker
Relevant to the content of this educational activity, the following individual(s) have a conflict(s) with ineligible companies to disclose. The accredited provider has mitigated all relationships.
- Dinesh Khanna, MBBS, MSc - Speaker
- Consultant for: AbbVie, Actelion, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, CSL Behring, Horizon Therapeutics
- Grant or Research Support: Bristol Myers Squibb Company, Horizon Therapeutics USA, Pfizer Inc.
- Intends to discuss off-label uses of the following commercial product(s)/device(s) and agrees to inform learners of such.
Disclaimer
The information provided in this activity is for continuing education purposes only. It is not a substitute for a healthcare provider's independent medical judgment regarding diagnostic and treatment options for a specific patient's medical condition.
Available Credit
- 4.50 AMA PRA Category 1 Credits™
- 4.50 AOA 2-A
- 4.50 CE Contact Hour(s)